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Cutaneous squamous cell carcinomas (cSCCs) are the second most frequent cancers in fair-skinned
populations; yet, because of their genetic heterogeneity, the key molecular events in cSCC tumorigenesis
remain poorly defined. We have used single nucleotide polymorphism microarray analysis to examine genome-
wide allelic imbalance in 60 cSCCs using paired non-tumor samples. The most frequent recurrent aberrations
were loss of heterozygosity at 3p and 9p, observed in 39 (65%) and 45 (75%) tumors, respectively. Microdeletions
at 9p23 within the protein tyrosine phosphatase receptor type D (PTPRD) locus were identified in 9 (15%)
samples, supporting a tumor suppressor role for PTPRD in cSCC. In addition, microdeletions at 3p14.2 were
detected in 3 (5%) cSCCs, implicating the fragile histidine triad (FHIT) gene as a possible target for inactivation.
Statistical analysis revealed that well-differentiated cSCCs demonstrated significantly fewer aberrations than
moderately and poorly differentiated cSCCs; yet, despite a lower rate of allelic imbalance, some specific
aberrations were observed equally frequently in both groups. No correlation was established between the
frequency of chromosomal aberrations and immune or human papillomavirus status. Our data suggest that
well-differentiated tumors are a genetically distinct subpopulation of cSCC.
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INTRODUCTION
Keratinocyte skin cancers, consisting basal cell carcinoma
and cutaneous squamous cell carcinoma (cSCC), represent an
important cause of morbidity in fair-skinned populations and
their incidence is increasing worldwide (de Vries et al.,
2005). Ultraviolet radiation is the principal carcinogen
implicated in keratinocyte skin cancer development (Arm-
strong and Kricker, 2001). Substantial data indicate that
dysregulation of the Sonic Hedgehog pathway is a key event
in basal cell carcinoma tumorigenesis (reviewed in Boukamp,
2005). In contrast, cSCC display much more genetic
heterogeneity, with several studies reporting recurrent
aberrations on many chromosomes (Quinn et al., 1994;
Ashton et al., 2003; Clausen et al., 2006; Purdie et al., 2007).
An etiological cofactor role in keratinocyte skin cancer has
also been suggested for beta genus human papillomaviruses
(HPVs). Beyond a demonstrated role in cSCC tumorigenesis
in patients with the rare genetic disease epidermodysplasia
verruciformis (Majewski and Jablonska, 1995) their onco-
genic potential remains less well defined although the
presence of beta HPV in normal skin has been shown to be
a risk factor for keratinocyte skin cancers (Harwood et al.,
2004). Organ transplant recipients (OTRs) receiving immuno-
suppression are at 100-fold increased risk of cSCC compared
with immunocompetent (IC) individuals and their tumors
may be more aggressive (Glover et al., 1997). It has been
suggested that OTR cSCCs display fewer chromosomal
aberrations than IC tumors (Rehman et al., 1997), possibly
reflecting differing etiologies, but this observation remains to
be confirmed.
SCC may be categorized as well, moderately and poorly
differentiated depending on the degree of keratinization and
cellular atypia. A greater percentage of poorly differentiated
SCCs metastasize compared with well-differentiated counter-
parts (17 vs 0.6%, respectively) (Breuninger et al., 1990).
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Previously, in a smaller series of tumors, we reported that
well-differentiated cSCC show a lower rate of allelic
imbalance than moderately or poorly differentiated tumors
although certain specific aberrations occur equally
frequently, suggesting that these tumors may constitute a
genetically distinct subpopulation of cSCC (Purdie et al.,
2007). However, this study was not sufficiently powered to
enable stratification for two important potential confounding
factors: HPV status and immune status. Here we have used
microarray-based single nucleotide polymorphism (SNP)
analysis to investigate whether a correlation exists between
the genetic profile and immune status and/or HPV status of
cSCC. In addition, we have used a larger series of samples to
examine our previous hypothesis that well-differentiated
tumors may be genetically distinct from other cSCCs.
RESULTS AND DISCUSSION
SNP microarray analysis was performed on a series of 60
primary cSCCs. Tumor DNA was analyzed concomitantly
with paired non-tumor DNA to permit the accurate identi-
fication of tumor-specific genetic events. Data included those
from 16 cSCCs previously analyzed using 10K SNP micro-
arrays (Purdie et al., 2007). Statistical analysis was restricted
to gross chromosomal aberrations greater than approximately
600 kb as a comparison of data from two cSCCs analyzed on
both 10 and 250K SNP microarrays revealed that aberrations
of this size were reliably detected by both microarrays.
Histopathologic evaluation of the 60 cSCCs revealed that
29 were well differentiated, 21 moderately differentiated, and
10 poorly differentiated. Keratoacanthomas were specifically
excluded from this study. Allelic imbalance was observed at
1–9 chromosomes (median of 5) in well-differentiated tumors
compared with 5–21 chromosomes (median of 9) in
moderately and poorly differentiated tumors (Table 1;
complete data in Table S1). Well-differentiated cSCC had
significantly fewer chromosomes displaying allelic imbalance
than moderately or poorly differentiated cSCC (Po0.001 in
both the cases) and a linear trend was shown to exist with
respect to differentiation status (Po0.001). No significant
difference existed between the numbers of chromosomes
with aberrations in moderately and poorly differentiated
cSCCs (P¼0.645) nor was there any significant difference
between these two groups when the comparison was
restricted to the number of chromosomes showing loss of
heterozygosity (LOH) or gain events alone (P¼1 and 0.092,
respectively). Similar results were obtained when the 16
previously reported cSCCs were excluded from the analysis
(Table S2). Despite a lower rate of allelic imbalance, certain
specific aberrations were as frequent in well-differentiated as
in moderately or poorly differentiated tumors (Figure 1). For
example, there was no significant difference between well-
differentiated and other cSCCs in the frequency of LOH at 3p
(P¼0.235) or gain at 3q (P¼0.815) or 9q (P¼0.839).
Hierarchical clustering was used to investigate the genetic
similarity between individual tumors. A high proportion of
well-differentiated cSCC clustered into a separate subset from
the majority of moderately and poorly differentiated cSCCs
(Figure 2). Taken together, these data support the hypothesis
that well-differentiated tumors demonstrate a characteristic
genotype and constitute a discrete subpopulation of cSCCs.
One early study using low-resolution microsatellite
analysis reported that the rate of LOH in OTR cSCCs was
less than half of that observed in IC cSCCs and proposed that
this reflected the influence of immune status on the molecular
pathogenesis of tumors (Rehman et al., 1997). However, we
observed no significant difference (P¼ 0.396) between the
number of chromosomes showing aberrations in OTR and IC
tumors (Table 1; complete data provided in Table S1). As the
earlier study focused on LOH alone, we also analyzed LOH
and gain events separately: no significant difference existed
between the number of chromosomes showing LOH or gain
in OTR and IC cSCCs (P¼ 0.450 and 0.639, respectively).
Similar results were obtained when the 16 previously
published cSCC were analyzed separately from the other
tumors (Table S2). A probable explanation for the discre-
pancy between these results and the previous finding lies in
the fact that 60% (9/15) of OTR cSCCs from the earlier study
were well differentiated compared with only 35% (7/20) of IC
cSCCs. Thus, we propose that the finding of an apparently
lower frequency of allelic loss in the OTR tumors in this
previous study was confounded by the genetic fingerprint
associated with differentiation status rather than immune
status per se.
The oncogenic potential of beta genus HPV, whose DNAs
are prevalent in cSCC, remains unclear (reviewed in Nindl
et al., 2007). Differences in chromosomal aberrations
between HPV-positive and -negative cSCCs could indicate
diverse genetic mechanisms of tumor development, provid-
ing support for an etiological role for HPV. Statistical analysis
established that no correlation existed between the number of
chromosomes demonstrating aberrations and HPV status
(P¼0.847). Similar results were obtained when the 16
previously published cSCCs were analyzed separately from
the other tumors (Table S2). Earlier data (Stockfleth et al.,
2004) suggest that HPV DNA prevalence is lower in IC than
OTR cSCC. A previous study from this laboratory using a
degenerate nested PCR method detected beta HPV in 80%
OTR cSCC, compared with only 30% IC cSCC (Harwood
et al., 2000). Conversely, in the current study beta HPV DNAs
were identified in similar proportions of IC (78%, 14/18) and
OTR (74%, 29/39) tumors. One explanation for the dis-
crepancy here is our use of a new and highly sensitive PCR-
reverse hybridization assay capable of identifying HPV DNA
at levels below the detection threshold of earlier methods (de
Koning et al., 2006), potentially resulting in a dispropor-
tionate increase in HPV detection among IC samples where
viral copy number may be lower (Pfister, 2003; Stockfleth
et al., 2004).
The most frequent aberration detected in the cSCC series
was LOH at 9p, observed in 45 of 60 (75%) samples
(Figure 1). Analysis of SNP call signal intensity data revealed
that 20% (9/45) of 9p LOH events were copy number neutral
and hence indicative of acquired uniparental disomy,
extending our previous finding that uniparental disomy is a
key mechanism of LOH in cSCC (Purdie et al., 2007). In the
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initial series of 16 cSCCs, we identified a frequent homo-
zygous microdeletion at 9p23 within the protein tyrosine
phosphatase receptor type D (PTPRD) locus. These data
implicated PTPRD as a candidate tumor suppressor gene in
cSCC and raised the possibility that, in addition to the
established CDKN2A tumor suppressor locus (Kubo et al.,
1997), 9p LOH may be important for the inactivation of
PTPRD. We have extended this finding by identifying PTPRD
microdeletions in 6 of the 44 additional cSCCs analyzed in
the current study, making a total of 9 of 60 (15%) cSCCs
(Table 2). Two of the nine cSCCs demonstrated metastatic
potential and four of the remaining seven cSCCs with PTPRD
microdeletions were diagnosed as poorly differentiated,
although poorly differentiated tumors comprised a minority
of our sample series (10/60 cSCCs); these data suggested that
PTPRD inactivation may be associated with more aggressive
tumors. We also observed homozygous microdeletions with-
in the CDKN2A locus at 9p21.2 or 9p21.3 in three samples,
confirming the previous finding that this tumor suppressor
gene may be inactivated by both genetic and epigenetic
mechanisms (Brown et al., 2004).
LOH at 3p was another frequent aberration, observed in
39 (65%) tumors and involving the whole of 3p in 23 (59%)
of these. Two cSCCs from patients 26 and 52 displayed a
homozygous microdeletion at 3p14.2 on a background of
LOH across 3p (Figure 3) whereas tumor T20 exhibited
extensive LOH at the telomeric end of 3p (3pter-3p21.31) in
Table 1. Allelic imbalance in 60 SCCs
ID1
Allelic
imbalance2
Histological
diagnosis
Immune
status HPV
1 15 Poorly differentiated3 RT +
2 3 Well differentiated4 CT 
3 7 Moderately differentiated RT +
4 3 Well differentiated RT +
5 6 Well differentiated RT 
6 3 Well differentiated RT +
7 5 Well differentiated RT +
8 10 Moderately differentiated RT 
9 5 Poorly differentiated IC +
10 8 Moderately differentiated IC +
11 7 Well differentiated IC +
12 6 Moderately differentiated IC +
13 9 Moderately differentiated IC +
14 11 Moderately differentiated IC +
15 12 Moderately differentiated IC 
16 10 Moderately differentiated IC +
17 9 Well differentiated RT +
18 6 Moderately differentiated RT +
19 6 Moderately differentiated RT +
20 11 Moderately differentiated IC 
21 9 Well differentiated RT +
22 9 Moderately differentiated RT +
23 6 Moderately differentiated IC +
24 9 Moderately differentiated IC 
25 8 Well differentiated IC +
26 9 Poorly differentiated PUVA 
27 2 Well differentiated RT +
28 3 Well differentiated RT 
29 8 Moderately differentiated RT 
30 3 Well differentiated RT +
31 9 Poorly differentiated RT +
32 11 Moderately differentiated RT 
33 6 Well differentiated CT +
34 7 Moderately differentiated RT 
35 11 Moderately differentiated PUVA 
36 5 Well differentiated IC +
37 16 Moderately differentiated RT +
38 3 Well differentiated IC 
39 8 Moderately differentiated IC +
40 13 Poorly differentiated IC +
41 6 Well differentiated RT 
42 8 Well differentiated RT +
43 11 Poorly differentiated IC +
44 6 Poorly differentiated RT +
Table 1. Continued
ID1
Allelic
imbalance2
Histological
diagnosis
Immune
status HPV
45 7 Well differentiated RT +
46 6 Well differentiated RT 
47 2 Well differentiated RT +
48 14 Moderately differentiated CLL 
49 2 Well differentiated RT +
50 7 Well differentiated CT +
51 6 Well differentiated RT +
52 17 Poorly differentiated RT +
53 5 Well differentiated RT +
54 1 Well differentiated RT 
55 2 Well differentiated RT +
56 4 Well differentiated RT +
57 21 Poorly differentiated RT +
58 4 Well differentiated RT +
59 5 Poorly differentiated IC +
60 5 Well differentiated RT +
CLL, chronic lymphocytic leukemia; CT, cardiac transplant recipient; IC,
immunocompetent individual; PUVA, patients receiving psoralen and
UVA photochemotherapy; RT, renal transplant recipient.
1Sample numbers 1–16 were published previously (Purdie et al., 2007).
2Number of chromosomes with allelic imbalance
3All tumors were invasive SCC.
4Well-differentiated SCC did not include keratoacanthomas.
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conjunction with a homozygous 3p14.2 microdeletion in a
heterozygous region of 3p. All microdeletions mapped to a
region at 60.41–61.16Mb, within the locus of fragile histidine
triad (FHIT) gene. FHIT is a recognized tumor suppressor
gene that is inactivated in several epithelial cancers including
lung cancer (Sozzi et al., 1996) and breast cancer (Negrini
et al., 1996), although its role in cSCC remains unclear. One
previous study (Sikkink et al., 1997) reported that two of five
cSCC tumors showed abnormal FHIT transcripts whereas
another (Popp et al., 2002) found that three cSCC lines with
3p loss expressed normal FHIT transcripts, albeit at much
reduced levels in two cases. However, the microsatellite
marker analysis and comparative genomic hybridization
(CGH) used did not permit fine mapping of the genetic
changes underlying these expression data. Our data from
high-resolution SNP microarray analysis provide the first
reported example of a homozygous microdeletion within this
locus in cSCC. Although it is possible that expression analysis
may reveal abnormal FHIT transcripts in a larger subset of
tumors, the low frequency of the 3p14.2 microdeletion
within our samples, together with the observation that T20
displayed extensive LOH on 3p separate from the 3p14.2
microdeletion, suggests that FHIT is unlikely to be the only
target on 3p. Indeed, early 3p deletion mapping studies in
other cancers (Hibi et al., 1992; Maestro et al., 1993) have
demonstrated the presence of three distinct deleted regions in
several tumors, 3pter-3p24, 3p21, and 3p 14.2–3p12,
implying that 3p loss may inactivate multiple tumor
suppressor genes.
Other recurrent events included LOH at 13q and 8p, each
observed in 23 (38%) tumors and chromosomal gain on 3q
(26 tumors; 43%), 8q (23 tumors; 38%), and 9q (21 tumors;
35%). Our data are consistent with the results of earlier
research using polymorphic microsatellite markers or CGH to
examine the genetics of cSCC (Quinn et al., 1994; Ashton
et al., 2003), where allelic imbalance on chromosomes 3, 9,
and 13 was among the predominant aberrations reported. In
contrast, a recent study (Clausen et al., 2006) using CGH to
examine cSCC including 11 tumors from our laboratory
found that 9p loss was a minor aberration, occurring in only
3.2% (1/31) SCCs. Loss of 3p and 13q was also observed less
frequently, in 19.4% (6/31) and 12.9% (4/31) tumors,
respectively. The most common chromosomal aberration
was gain at 1p, identified in 41.9% (13/31) SCCs compared
chr1 chr2 chr3 chr4 chr5
chr6 chr7 chr8 chr9 chr10
chr11 chr12 chr13 chr14 chr15 chr16 chr17
chr18 chr19 chr20 chr21 chr22 chrX chrY
Figure 1. Ideogram summarizing allelic imbalance in well-differentiated cSCCs (light colored lines) and moderately and poorly differentiated cSCCs (dark
colored lines). LOH events are indicated to the left of chromosomes with deletion shown in green and uniparental disomy in blue and gains are indicated to the
right in red.
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with only 9/60 (15%) samples in the present study. Overall
more gains than losses of chromosomal material (ratio of
1.65:1) were reported using CGH (Clausen et al., 2006)
whereas we observed that LOH (deletion and uniparental
disomy) predominated over gain events by a ratio of 1.5:1
(Table S1). These discrepancies may in part reflect the
limitations of CGH for identifying LOH and possible
preferential detection of amplifications: deleted regions must
be as large as 5–10Mb to be detected whereas amplifications
of 1Mb can be identified (Forozan et al., 1997). Furthermore,
CGH is unable to detect copy number neutral LOH
(uniparental disomy), which accounted for 20% of 9p LOH
and 22% 13q LOH in the current study. Conversely, the
lower frequency of 1p gain observed here combined with the
overall predominance of LOH over amplifications detected
implies that SNP microarray analysis may display greater
sensitivity for identifying LOH than gain events. Methodolo-
gical differences are likely to have been another contributory
factor: in the two earlier investigations that reported a high
T9
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Figure 2. Cluster dendrogram of cSCCs. Distances between samples relate to
agreement in aberration as a ratio of total number of aberrations. Well-
differentiated cSCCs are indicated in green, moderately differentiated in
orange, and poorly differentiated in red.
Table 2. PTPRD microdeletions in nine SCCs
SCC ID Start position1 End position Histological diagnosis
3 9.082 9.22 Moderately differentiated3
10.42 10.51
9 9.16 9.76 Poorly differentiated
124 8.55 9.38 Moderately differentiated
21 8.98 9.87 Well differentiated
254 9.22 9.83 Well differentiated
26 9.13 9.99 Poorly differentiated
39 9.25 9.58 Moderately differentiated
40 9.47 9.86 Poorly differentiated
524 9.37 9.48 Poorly differentiated
SCC, squamous cell carcinoma; PTPRD, protein tyrosine phosphatase
receptor type D.
1Start and end positions of the microdeletion are indicated in Mb.
2Tumor demonstrated two regions of microdeletion.
3SCC T3 and T12 demonstrated metastatic potential as reported
previously (Purdie et al., 2007).
4Microdeletions in these tumors were hemizygous, all others were
homozygous.
SCC ID
T20
T26
T52
3p14.2
m
icrodeletion
Figure 3. Display of copy number ratios on chromosome 3 reveals a 3p14.2
microdeletion within the FHIT locus. A running average of two consecutive
tumor/non-tumor signal value ratios is plotted on a log2 scale according to
chromosomal position. Upper line represents log2(2) and lower line
represents log2(0.5). Microdeletions mapped to the following regions: SCC
T20, 60.46–60.61Mb; SCC T26, 60.41–60.58Mb; SCC T52, 60.41–61.16Mb.
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frequency of LOH at 9p and other chromosomes (Quinn
et al., 1994; Ashton et al., 2003) tumors were microdissected
before DNA extraction as in our protocol, whereas the more
recent CGH study (Clausen et al., 2006) performed analysis
on a central section of the entire lesion. Depending on the
proportion of stromal tissue and hence non-tumor DNA
present within samples, it seems possible that some LOH
events may have been masked, whereas gains of chromo-
somal material might still be detected if the degree of
amplification were sufficiently large.
In summary, we have used genome-wide SNP microarray
analysis to confirm our previous hypothesis that well-
differentiated tumors are a genetically distinct subpopulation
of cSCC. Contrary to earlier research (Rehman et al., 1997),
we found no significant difference in the frequency of allelic
imbalance in OTR and IC cSCCs nor were we able to
establish any correlation between the frequency of chromo-
somal aberrations and HPV status. Extensive LOH at 3p and
9p were observed in a majority of samples, consistent with
previous data. Loss of 9p may entail the inactivation of
PTPRD, recently implicated as a candidate tumor suppressor
gene in cSCC (Purdie et al., 2007). Here, we demonstrate
PTPRD microdeletions in 9 of 60 (15%) cSCCs and identify
FHIT on 3p14.2 as another possible target for inactivation.
Our findings demonstrate the effectiveness of genome-wide
SNP microarray analysis as a means of unraveling the genetic
complexity of cSCC.
MATERIALS AND METHODS
A total of 60 primary cSCCs were analyzed, including 16 primary
cSCCs described in an earlier study (Purdie et al., 2007). Of these
tumors, 42 were from immunocompromised individuals (39 were
receiving immunosuppressive therapy (3 cardiac and 36 renal
transplant recipients), 2 were receiving psoralen and UVA photo-
chemotherapy for psoriasis, and 1 had chronic lymphocytic
leukemia). Ethical approval for this investigation was obtained from
the East London and City Health Authority local ethics committee
and the study was conducted according to the Declaration of
Helsinki Principles. All patients participating in the study provided
written, informed consent.
All histopathologic diagnoses were confirmed by a single
experienced dermatopathologist (RC). Samples were enriched for
cSCC keratinocytes, DNA was extracted from cSCC and non-tumor
control blood samples and subjected to 250K Nsp SNP array analysis
as previously described (Purdie et al., 2007). The presence of beta
HPV was investigated in cSCC DNA samples using the RHA kit skin
(beta) HPV (Diassay BV, Rijswijk, the Netherlands) according to the
manufacturer’s instructions.
Statistical analyses were carried out using Poisson regression. We
used a generalized linear model with a Poisson distribution imposed
on the number of chromosomes per patient with at least one event,
and a log link function. Sequential analysis of deviance was carried
out on the model that was fitted with terms representing differentia-
tion effect, immune effect, and HPV effect, respectively, using a w2-
test on the deviances. To test for a linear trend with respect to
differentiation status, P-values were calculated against the null
hypothesis that the linear trend of count against differentiation status
had zero slope. This analysis was all carried out using the ‘‘glm’’
function within the statistical environment R (R Development Core
Team, 2007). For individual comparisons among the differentiation
subgroups, we used Tukey’s contrasts between the pairwise
comparisons, using the multcomp (Hothorn et al., 2008) package
within R to adjust for the multiple comparison situation. Hierarchical
clustering was carried out in R using hclust with an asymmetrical
binary metric between samples, where the asymmetric binary
distance between pairs of samples was calculated as the number
of aberrations observed in just one sample expressed as a proportion
of the number of aberrations in one or both of the samples.
Intercluster similarities were calculated using Ward’s agglomeration
method (Ward, 1963).
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